unexplained weakness or dizziness Allergic reactions: facial swelling, difficulty breathing, widespread rash, or severe skin reactions Cardiovascular symptoms: chest pain, sudden shortness of breath, weakness on one side of the body, slurred speech, or severe headache Severe dehydration: inability to keep fluids down, reduced urination, extreme thirst, confusion, or rapid heartbeat Signs of pancreatitis: severe, persistent abdominal pain that may radiate to the back, with or without vomiting Contact your GP or call NHS 111 within 24 hours if you experience: Persistent or worsening nausea and vomiting that prevents adequate nutrition or hydration New or significantly worsened abdominal pain that differs from typical Wegovy-related discomfort Signs of fluid retention such as sudden weight gain, swelling of ankles or legs, or increased breathlessness Unexplained bruising or bleeding Symptoms suggesting worsening of pre-existing conditions (elevated blood pressure, reduced urine output) Routine consultation is advisable before starting naproxen if you are already taking Wegovy, particularly if: You require naproxen for more than a few days You have a history of peptic ulcer disease, gastrointestinal bleeding, or inflammatory bowel disease You have cardiovascular disease, hypertension, or kidney problems You are taking other medications that may interact with NSAIDs, including anticoagulants (warfarin, DOACs), antiplatelet agents (aspirin, clopidogrel), corticosteroids, or SSRIs Your healthcare provider can assess your individual risk profile and determine whether naproxen is the most appropriate analgesic option for your circumstances
Observational studies show that patients with diabetes taking tirzepatide were 60% less likely to be diagnosed with anxiety compared to non-users
Dulaglutide (Trulicity) Dulaglutide is a GLP-1 receptor agonist that is given once a week
This medication is an excellent option for those looking to lose weight with minimal effort and maximum results
This distinction matters when switching between peptides or when researchers accidentally apply semaglutide calculation logic to retatrutide, a common and potentially significant mistake
